Lu Zhang , Amy Kempf , Inga Nehlmeier , Nianzhen Chen , Luise Graichen , Anna-Sophie Moldenhauer , Metodi V. Stankov , Christine Happle , Sebastian R. Schulz , Alexandra Dopfer-Jablonka , Hans-Martin Jäck , Georg M.N. Behrens , Stefan Pöhlmann , Markus Hoffmann
{"title":"Host cell entry efficiency and neutralization sensitivity of the SARS-CoV-2 MC.10.1 variant","authors":"Lu Zhang , Amy Kempf , Inga Nehlmeier , Nianzhen Chen , Luise Graichen , Anna-Sophie Moldenhauer , Metodi V. Stankov , Christine Happle , Sebastian R. Schulz , Alexandra Dopfer-Jablonka , Hans-Martin Jäck , Georg M.N. Behrens , Stefan Pöhlmann , Markus Hoffmann","doi":"10.1016/j.virol.2025.110675","DOIUrl":null,"url":null,"abstract":"<div><div>New SARS-CoV-2 variants continue to emerge and may cause new waves of COVID-19. Antibody evasion is a major driver of variant emergence but variants can also exhibit altered capacity to enter lung cells and to use ACE2 species orthologues for cell entry. Here, we assessed cell line tropism, usage of ACE2 orthologues and antibody evasion of variant MC.10.1. This variant arose from the highly prevalent KP.3.1.1 variant, reached a prevalence of 10–15 % in certain countries in the spring of 2025 and contains a single amino acid mutation in the spike (S) protein, A435S, relative to the KP.3.1.1 S protein. We found that MC.10.1 and the parental KP.3.1.1 S protein show similar expression and similar capacity to fuse cells and to use ACE2 orthologues from different species for entry. In contrast, MC.10.1 S protein-driven entry into Calu-3 lung cells was reduced as compared to the KP.3.1.1 S protein. Finally, MC.10.1 S protein-bearing particles were less susceptible to neutralization by antibodies induced upon vaccination with the JN.1 booster vaccine as compared to their counterparts bearing KP.3.1.1 S protein. Collectively, our results indicate increased antibody evasion but reduced cell entry efficiency of variant MC.10.1.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"612 ","pages":"Article 110675"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225002892","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
New SARS-CoV-2 variants continue to emerge and may cause new waves of COVID-19. Antibody evasion is a major driver of variant emergence but variants can also exhibit altered capacity to enter lung cells and to use ACE2 species orthologues for cell entry. Here, we assessed cell line tropism, usage of ACE2 orthologues and antibody evasion of variant MC.10.1. This variant arose from the highly prevalent KP.3.1.1 variant, reached a prevalence of 10–15 % in certain countries in the spring of 2025 and contains a single amino acid mutation in the spike (S) protein, A435S, relative to the KP.3.1.1 S protein. We found that MC.10.1 and the parental KP.3.1.1 S protein show similar expression and similar capacity to fuse cells and to use ACE2 orthologues from different species for entry. In contrast, MC.10.1 S protein-driven entry into Calu-3 lung cells was reduced as compared to the KP.3.1.1 S protein. Finally, MC.10.1 S protein-bearing particles were less susceptible to neutralization by antibodies induced upon vaccination with the JN.1 booster vaccine as compared to their counterparts bearing KP.3.1.1 S protein. Collectively, our results indicate increased antibody evasion but reduced cell entry efficiency of variant MC.10.1.
期刊介绍:
Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.